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ATRThe ATR–ATRIP protein kinase complex plays a crucial role in the cellular response to replication
stress and DNA damage. Recent studies found that ATR could be activated in response to hypoxia
and be involved in hypoxia-induced genetic instability in cancer cells. However, the underlying
mechanisms for ATR activation in response to hypoxic stress are still not fully understood. We
reported that ATRIP is a direct target of HIF-1. Silencing the expression of HIF-1a in cancer cells
by RNA interference abolished hypoxia-induced ATRIP expression. Silencing the expression of ATRIP
by RNA interference abolished hypoxia induced ATR activation and CHK1 phosphorylation in cancer
cells. Taken together, these data shed novel insights on the mechanism of hypoxia-induced activa-
tion of the ATR pathway.
 2013 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
In eukaryotic cells, several checkpoint-control mechanisms help
to preserve the integrity of the genome [1]. Members of the phos-
phoinositide kinase-related family of protein kinases (PIKKs), such
as ATM and ATR, are key upstream regulators of checkpoint re-
sponses [2,3]. ATM is activated following double-strand breaks
while ATR activation is associated with single-strand breaks and
stalled replication forks [4,5]. ATR is recruited to single-stranded
DNA via ATR-interacting protein (ATRIP). In response to genomic
stress, the ATR interacting protein (ATRIP) binds and is phosphor-
ylated by the DNA damage- and checkpoint-activated kinase ATR
[6]. ATRIP directly interacts with replication protein A (RPA) that
results in the recruitment of phosphorylated ATR/ATRIP to stalled
replication forks and sites of DNA damage [7]. ATR/ATRIP coordi-
nates DNA repair and cell cycle progression in conjunction with
several key regulatory proteins, including Rad17 and the 9-1-1
complex [8]. ATR and ATRIP are essential for the DNA damage re-
sponse and replication-induced cell cycle arrest [7,9].
Intratumoral hypoxia is a hallmark of solid cancer. A hypoxic
microenvironment initiates multiple cellular responses, including
proliferation and angiogenesis, resulting in the development andprogression of cancer [10]. The homeostatic response to hypoxia
is predominantly mediated by the transcription factor hypoxia-
inducible factor (HIF)-1 which is a heterodimer that consists of
two basic helix-loop-helix proteins of the PAS family—a hypoxia
regulated a-subunit (HIF-1a or HIF-2a) and a constitutive b-sub-
unit (HIF-1b) [11]. Under normoxic conditions, HIF-a subunits
are hydroxylated on proline residues by a class of prolyl hydroxy-
lases. Then prolyl-hydroxylated HIF-a is recognized and targeted
for ubiquitin-mediated destruction by the von Hippel–Lindau
(VHL) tumor suppressor protein, which is a substrate recognition
component of an E3 ubiquitin ligase. Under hypoxic conditions,
HIF-a remains unmodiﬁed by prolyl hydroxylases and thereby
escapes recognition by VHL and destruction [12]. Thus escaped
HIF-a dimerizes with HIF-1b, translocates to the nucleus and
activates genes of the hypoxia response by binding to the core
sequence (RCGTG) of the hypoxic responsive element (HRE) with
additional recruitment of the co-activators CBP/p300 [13].
Mutations in VHL can be found in familial and sporadic clear cell
carcinomas of the kidney, hemangioblastomas of the retina and
central nervous system, and pheochromocytomas, underscoring
its gatekeeper function in the pathogenesis of these tumors.
Tissue-speciﬁc gene targeting of VHL in mice has demonstrated
that efﬁcient execution of pVHL-mediated HIF proteolysis under
normoxia is fundamentally important for survival, proliferation,
differentiation and normal physiology of many cell types. As a
Fig. 1. Hypoxia and hypoxia reagent induce ATRIP expression. (A) mRNA levels of ATRIP in MCF7, HeLa and HepG2 cells under normoxia, hypoxia or 100 lM DFO
(deferoxamine mesylate salt) for 24 h were determined by real-time PCR assay. (B–D) Western blot analysis of ATRIP, HIF-1a and Actin in MCF6 (B), HeLa (C) and HepG2 (D)
cells under normoxia (N) or hypoxia (H) condition. (E) HepG2 cells were cultured in hypoxia for the indicated length of time. Lysate of cells were assayed byWestern blot with
indicated antibodies.
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in many human cancers [14].
Emerging evidence suggests that hypoxia can also induce genet-
ic instability in cancer cells [15,16]. Several DNA damage response
factors are activated in response to hypoxia and subsequent reoxy-
genation, including ATM/ATR, Chkl/Chk2 and BRCA1 [17–20].
These ﬁndings reveal that hypoxia induces an acute DNA damage
response in cancer cells by activating key DNA damage sensors.
However, how these sensors are activated by hypoxia is largely un-
known. So, it is necessary to understand the mechanisms underly-
ing control of ATR kinase activity in response to hypoxic stress.
Here, we show that both the mRNA and protein levels of ATRIP
are markedly increased in human cancer cell lines in response to
hypoxia. We also found that ATRIP is a direct target gene of HIF-
1. The increased ATRIP then activates the ATR signaling pathway
under hypoxia. Our ﬁndings thus help us to understand how ATR
is activated by hypoxia, which may have profound biological and
therapeutic implications for cancer.2. Materials and methods
2.1. Cell culture
HeLa, MCF7, HepG2, 293T and IMR90 cell lines were cultured in
DMEM medium supplemented with 10% fetal bovine serum (FBS)
(Gibco, CA, USA) as well as 100 U/ml penicilin and 100 lg/ml strep-
tomycin. For hypoxia treatment, cells were cultured in a hypoxia
chamber ﬂushed with 0.1% O2 and 5% CO2 with balance of 95%
nitrogen at 37 C. Control cells were placed in a 5% CO2 and 95%
air incubator (20% O2) at 37 C.
2.2. SiRNA and transfection
Small interfering (si) RNA against HIF-1a and ATRIP were pur-
chased from Dharmacon (USA). As a negative control, a siRNA se-
quence targeting green ﬂuorescent protein (non-targeting siRNA)
was used. All transient transfections were performed using Lipo-
Fig. 2. HIF-1 mediates hypoxia-induced ATRIP expression. (A and B) HIF-1a plasmid was transfected into HeLa (A) and HepG2 (B) cells for 36 h. Lysate of these cells were
assayed by Western blot with indicated antibodies. (C) mRNA levels of HIF-1a in HeLa cells transfected with siRNA targeting HIF-1a or non-targeting siRNA were determined
by real-time PCR assay. (D) HeLa cells were transfected with siRNA targeting HIF-1a or non-targeting siRNA for 24 h and cultured under hypoxic condition for additional 24 h.
Lysate of these cells were assayed by Western blot with indicated antibodies. (E) mRNA and protein levels of ATRIP in HeLa cells transfected with siRNA targeting HIF-1a or
non-targeting siRNA under normoxia (N) or hypoxia (H) condition were determined by real-time PCR assay andWestern blot. (F) mRNA levels of ATRIP in RCC4 and RCC4/VHL
cells were determined by real-time PCR assay. (G) Western blot analysis of ATRIP, HIF-1a, VHL and Actin in RCC4 and RCC4/VHL cells under normoxia condition.
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instructions.
2.3. RNA isolation and real-time PCR
Total RNAs from HepG2 and IMR90 cells were isolated by TRIzol
reagent, and reverse transcriptions were performed by Takara RNA
PCR kit following the manufacturer’s instructions. In order to quan-
tify the transcripts of the interest genes, real-time PCR was per-
formed using a SYBR Green Premix Ex Taq (Takara, Japan) on
Light Cycler 480 (Roche, Switzerland). ATRIP transcript expression
was normalized to b-actin mRNA expression using the DCt method
and the linearized DCt (i.e. 2  DCt) was used for comparative pur-
poses. The primer sequences used are available upon request.
2.4. Western blot
Cells were harvested and lysed with ice-cold lysis buffer
(50 mM Tris–HCl, pH 7.4, 100 mM DTT, 2% w/v SDS, 10% glycerol).
After centrifugation at 20000g for 10 min at 4 C, proteins in the
supernatants were quantiﬁed and separated by 10% SDS–PAGE,
transferred to NC membrane. After blocking with 5% non-fat milk,
membranes were immunoblotted with antibodies as indicated, fol-
lowed by HRP-linked secondary antibodies. The signals were de-
tected by Millipore SuperSignal HRP Substrate kit according to
manufacturer’s instructions.
2.5. Chemicals and antibodies
Deferoxamine mesylate salt (DFO) was purchased from
Sigma–Aldrich (St. Louis, MO), dissolved in DMSO. The antibodiesfor ATRIP (#2737), ATR (#2790), Chk1 (2G1D5) (#2360), Phos-
pho-Chk1 (Ser345) (133D3) (#2348), Histone H2A.X (#2595),
Phospho-Histone H2A.X (Ser139) (#2577), VHL (#2738), Claspin
(#2800) and HIF-1a (#3716) were purchased from Cell Signaling
Technology. The antibodies for TopBP1 (ab2402) and Hus1
(ab96297) were purchased from Abcam. Actin (A2228) antibody
was purchased from Sigma.2.6. Luciferase assays
The ATRIP promoter was ampliﬁed from a human genomic DNA
template and inserted into pGL3 basic vector (Promega). A mutant
HIF-1 binding motif was generated using a PCR mutagenesis kit
(Toyobo) with a primer (mutation sites underlined): 50-ctcaaa
cgcaacacgAAtgaatgctagggcag-30 and a reverse complement primer.
For luciferase reporter assays, HepG2 cells were seeded in 12-well
plates and transfected with the indicated plasmids. Cells were har-
vested 30 h after transfection. Luciferase activities were measured
using the Dual Luciferase Reporter Assay System (Promega, USA).
2.7. ChIP assays
Chromatin immunoprecipitation (ChIP) assay kits were used
(Upstate, USA). In short, HepG2 cells were ﬁxed with 1% formal-
dehyde to cross-link the proteins and DNA, after which DNA
was sheared to fragments of 200–800 bp by sonication in an
ultrasound bath on ice. The chromatin was then incubated and
precipitated with anti-IgG and anti-HIF-1a antibodies. The immu-
noprecipitated DNA fragments were detected using real-time PCR
analysis.
Fig. 3. Identiﬁcation and validation of a functional HRE in ATRIP promoter region. (A) Schematic diagrams of the regulating sequences with the putative HRE (black ovals) of
ATRIP. Mut: CG was changed into AA. (B) HeLa cells were transfected with the putative ATRIP HRE-luciferase reporter plasmids in the absence or presence of HIF-1a plasmid.
After 48 h of transfection, the luciferase activity was measured. Transfection efﬁciency was normalized by Renilla luciferase expression, and the results are presented as
activation over that for an empty vector. (C) The luciferase activity was measured in HepG2 cells with the methods described in (B). (D) HeLa cells were transfected with the
putative ATRIP HRE-luciferase reporter plasmids. 24 h after transfection, cells were culture under indicated conditions for additional 24 h, the luciferase activity was
measured. (E) Anti-IgG and anti-HIF-1a antibodies were used in the ChIP assays using HepG2 cells incubated with or without hypoxia.
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Data were summarized as mean ± S.E.M. Statistical signiﬁcance
was analyzed by one-way ANOVA followed by Turkey’s test using
SPSS 11.0 software (Chicago, IL, US). A value of P < 0.05 was consid-
ered signiﬁcant. Statistical signiﬁcance is displayed as ⁄P < 0.05,
⁄⁄P < 0.01 or ⁄⁄⁄P < 0.001.
3. Results
3.1. Hypoxia and hypoxia reagent induce ATRIP expression
To test whether ATRIP expression is regulated by hypoxia,
MCF7, HeLa and HepG2 cells were incubated under normoxia
(21% O2), hypoxia (1% O2) or medium containing 100 lM DFO
(deferoxamine mesylate salt) for 24 h. Real-time-PCR data revealed
an increased ATRIP mRNA level in the cells under hypoxic or DFO
treatment conditions (Fig. 1A). An increased ATRIP protein level
accompanying increased HIF-1a protein levels was also observed
in the cells under hypoxic condition (Fig. 1B–D). Indeed, hypoxia
induced the expression on ATRIP in HepG2 cells in a time depen-
dent manner (Fig. 1E). Moreover, ATRIP was the only DNA-damage
related protein that induced during hypoxia (Fig. S1). Taken to-
gether, these results demonstrate that ATRIP can be induced in
cells by hypoxia.
3.2. HIF-1 mediates hypoxia-induced ATRIP expression
HIF-1 is a global transcriptional regulator of the hypoxic
response. To test whether HIF-1 also mediates hypoxia-regulated
ATRIP expression, HIF-1a-expressing plasmid was transientlytransfected into HeLa and HepG2 cells. Notably, ectopic expression
of HIF-1a could signiﬁcantly up-regulate ATRIP expression in both
cell lines (Fig. 2A and B). To further investigate the role of HIF-1 in
the regulation of the expression of ATRIP, HeLa cells were transfec-
ted with siRNA targeting HIF-1a or non-targeting siRNA to silence
endogenous HIF-1a expression. The inhibition rate was evaluated
by both real-time PCR and Western blot (Fig. 2C and D). As ex-
pected, ATRIP mRNA and protein levels were markedly decreased
when HIF-1awas silenced under normoxic and hypoxic conditions
(Fig. 2E). Similar results were also observed in MCF7 and HepG2
cells (Data not shown). To determine if ATRIP expression was af-
fected by pVHL status, ATRIP mRNA and protein levels in normoxia
were examined in RCC4 renal cancer cells with mutant pVHL, and
in RCC4/VHL cells, an isogenic stable revertant of RCC4 expressing
wild-type pVHL [21]. Levels of ATRIP mRNA and proteins were re-
duced in cells with wild-type versus mutant pVHL (Fig. 2F and G).
Taken together, these data suggested that regulation of ATRIP by
hypoxia is HIF-1 dependent.
3.3. Identiﬁcation and validation of a functional HRE in ATRIP
promoter region
We next determined whether HIF-1a could be a transcriptional
regulator of the ATRIP gene. There is one potential HRE at 0.4 kb re-
gion upstream to the transcription start site of ATRIP
(Chr3:48,487,864-48,487,868, around 0.4 Kb upstream the TSS)
(Fig. 3A). HeLa cells were transfected with a reporter vector encod-
ing luciferase under control of the ATRIP promoter (WT-Luc). Con-
current expression of HIF-1a with the ATRIP reporter construct
increased ATRIP promoter activity (Fig. 3B), which was abrogated
by mutation of this HIF-1a DNA-binding site (CG-AA) in the ATRIP
Fig. 4. Hypoxia-induced ATR activation was mediated by ATRIP. (A) mRNA and protein levels of ATRIP in HepG2 cells transfected with siRNA targeting ATRIP or non-targeting
siRNA were determined by real-time PCR assay andWestern blot. (B) HepG2 cells transfected with siRNA targeting ATRIP or non-targeting siRNA were under normoxia (N) or
hypoxia (H) condition. Lysate of these cells were assayed by Western blot with indicated antibodies.
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promoter activity was also shown in HepG2 cells (Fig. 3C).
Moreover, hypoxia alone could signiﬁcantly stimulate the activity
of WT-Luc but not Mut-Luc (Fig. 3D). These observations indicated
that HIF-1a could bind to the promoter of ATRIP. To further
demonstrate that HIF-1 binds to the HRE in the ATRIP promoter,
we performed ChIP assay using antibodies against HIF-1a
(IgG as a negative control) in normoxic- and hypoxic-cultured
HepG2 cells. As depicted in Fig. 3E, HIF-1a but not IgG speciﬁcally
bound to the HRE sequence in the ATRIP promoter. In summary,
these results show that ATRIP is directly induced by HIF-1 under
hypoxia.
3.4. Hypoxia-induced ATR activation is mediated by ATRIP
Several studies have demonstrated that ATM and ATR are acti-
vated in response to hypoxia [17,20]. ATR is recruited to single-
stranded DNA via ATRIP [6]. Both ATR and ATRIP are essential for
the DNA damage response and replication-induced cell cycle arrest
[7]. On the basis of this, we hypothesized that hypoxia promotes
ATR activation through induction of ATRIP. To test this possibility,
HepG2 cells were transfected with siRNA targeting ATRIP or non-
targeting siRNA to silence endogenous ATRIP expression. The inhi-
bition rate was evaluated by both real-time PCR and Western blot
(Fig. 4A and B). In agreement with the previous study, ATR signal-
ing pathway was activated in HepG2 cells incubated under hypox-
ia, as evidenced by increased phosphorylation of ATR targets
including CHK1 and H2AX (Fig. 4B). However, these hypoxia-in-
duced effects were almost completely abolished when ATRIP was
silenced in HepG2 cells (Fig. 4B). Taken together, these data sug-
gested that ATRIP was required for hypoxia-induced ATR
activation.
4. Discussion
In the present study, we showed that ATRIP was induced by hy-
poxia in human cancer cells. We provided evidence that ATRIP is a
direct target gene of HIF-1. Hypoxia and ectopically expressed HIF-
1a protein signiﬁcantly increased ATRIP expression at both mRNA
and protein levels in cancer cell lines. Then, silencing of HIF-1a by
speciﬁc siRNA antagonized hypoxia-induced ATRIP expression.
Using luciferase reporter and ChIP assay, we found that HIF-1a di-
rectly bound to the HRE located at 386 to 381 of ATRIP gene,which is essential for HIF-1-induced ATRIP expression. Without
ATRIP, hypoxia induced ATR activation was dramatically de-
creased, indicating that ATRIP may be necessary for hypoxia in-
duced ATR activation. Thus, ATR signaling was, at least, partially
activated by induced ATRIP under hypoxia stress in cancer cells.
During the review process of our study, one interesting paper
described a positive regulation of ATR over HIF-1 [22]. Consistent
with our observations, ATR protein level was unchanged during
hypoxia. Our data support this work by indicating that ATR-acti-
vated HIF-1 further ampliﬁes ATR signaling through ATRIP induc-
tion to form a positive feedback loop in the process of hypoxia.
ATRIP could also be induced in non-transformed hypoxic IMR90
cells (Fig. S2). Both ATR and ATRIP are essential for the DNA dam-
age response and replication-induced cell cycle arrest. Non-trans-
formed hypoxic cells can undergo cell cycle arrest at the G1/S
interface without any alteration in their long-term viability [23],
suggesting the HIF-1-ATR-ATRIP axis may play a role in hypoxia-
induced cell cycle arrest in non-transformed cells. Future work
may focus on the role of the HIF-1-ATR-ATRIP axis in the regulation
of hypoxic non-transformed cells.
HIF-1 is a heterodimer that consists of two basic helix-loop-he-
lix proteins of the PAS family—a hypoxia regulated a-subunit (HIF-
1a or HIF-2a) and a constitutive b-subunit (HIF-1b). Both HIF-1a
and HIF-2a have been reported to be over-expressed in a series
of tumors [24,25]. Therefore, it would be interesting to investigate
the expression of ATRIP in human cancers. The relevance between
HIF-1a/HIF-2a and ATRIP should also be investigated as well in the
future.
ATRIP is required for the cellular response to DNA damage and
replication stress. ATRIP is phosphorylated by ATR and colocalizes
with ATR in cells treated with DNA damaging agents [26]. Previous
studies have also shown that the single-stranded DNA binding pro-
tein RPA (replication protein A) is necessary for the in vitro binding
of ATRIP to DNA and that loss of RPA prevents the formation of ATR
and ATRIP foci in cells treated with ionizing radiation [27]. How-
ever, whether RPA is required for hypoxia-induced ATR activation
and whether RPA is induced or activated by hypoxia remains un-
known. It would be interesting to understand the role of RPA in hy-
poxia-induced ATR activation.
In summary, these discoveries shed new insights on the mech-
anism of ATRIP expression regulation and hypoxia induced activa-
tion of the ATR signaling pathway. Ultimately, these data may
provide the rationale for the development of ATRIP inhibitors to
G. Ding et al. / FEBS Letters 587 (2013) 930–935 935prevent hypoxia-induced ATR activation and genetic instability in
cancer cells.
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